Immunocore Holdings plc reported the first quarter ended March 31, 2026 results: revenue $106.7 million, net income $13.0 million, EPS $0.25.
“2 ef20072537_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal”
William Pao was appointed as Director at Immunocore Holdings plc.
“the Board appointed William Pao, M.D., Ph.D. to serve as a Class II director of the Company, effective February 25, 2025.”
Travis Coy resigned as Director at Immunocore Holdings plc.
“In connection with his entry into the Employment Agreement, Mr. Coy resigned from the Company’s board of directors (the “Board”), effective as of the Effective Date.”
Travis Coy was appointed as Executive Vice President, Chief Financial Officer and Head of Corporate Development at Immunocore Holdings plc.
“On December 31, 2024, Immunocore LLC, an indirect, wholly owned subsidiary of Immunocore Holdings plc (“Parent” and, together with Immunocore LLC, the “Company”), entered into an employment agreement (the “Employment Agreement”) with Travis Coy, pursuant to which Mr. Coy will serve as the Company’s Executive Vice President, Chief Financial Officer and Head of Corporate Development as well as the Company’s principal financial officer, effective as of January 1, 2025 (the “Effective Date”).”
Brian Di Donato resigned as Chief Financial Officer at Immunocore Holdings plc.
“Mr. Brian Di Donato notified Immunocore Holdings plc (the “Company”) of his decision to resign as Executive Vice President, Chief Financial Officer and Head of Strategy and principal financial officer of the Company, effective December 31, 2024, to pursue another opportunity.”
Ranjeev Krishana was appointed as Class I director at Immunocore Holdings plc.
“the Board appointed Mr. Ranjeev Krishana to serve as a Class I director of the Company, effective May 28, 2024.”
Earnings Releases
Immunocore Holdings plc reported the first quarter ended March 31, 2024 results: revenue Total net product revenue ... was $70.3 million in the first quarter of 2024, net income Net loss for the first quarter of 2024 was $24.4 million, EPS The first quarter basic and diluted loss per share was $0.49.
“On May 8, 2024, Immunocore Holdings plc (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024, as well as other recent corporate updates.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.